Conference Reports for NATAP

Back

IAC 2018 - 22nd International AIDS Conference Amsterdam, The Netherlands July 22-27     Tony Fauci Dismisses Cure/Eradication - Slides at IAC on Vedolizumab Study Imbedded in his talk, where Fauci said.......in quotations marks just below - (10/17/18)   French Cohort / Integrase inhibitors and neuropsychiatric adverse events in a large prospective cohort (09/05/18)   Higher Prevalence NCI In Aging HIV-Infected Women Despite Lower Comorbidities Than Men (08/17/18)   Eliminating Excess CVD Risk for Diabetic Type2 - Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes (08/17/18)   Select Key IAC 2018 Highlight Reports / Coverage: ART drugs, PrEP, Aging/Comorbidities/Mortality/Fatty Liver/Heart & Kidney diseases (08/17/18)   PrEP & Prevention - HIV & HCV (08/17/18)   HIV Prevention at AIDS 2018 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (08/15/18)   Partners of people living with HIV (PLHIV): Findings from the positive perspectives survey (08/14/18)   Incidence and Prevalence of Diarrhea in HIV Clinical Trials in the Recent Post-cART Era: Analysis of Data From 38 Clinical Trials From 2008-2017 in Over 21,000 Patients (08/14/18)   High incidence of HCV (re-)infections among PrEP users in the Netherlands: implications for prevention, monitoring and treatment (08/09/18)   Prevalence and immuno-metabolic associations of frailty in older Australian men living with HIV: a crosssectional analysis (08/08/18)   Antiretroviral Treatment Maintenance Strategies and Blood Telomere Length Change (08/08/18)   Weight Gain After ARV Initiation Correlates with Increased Inflammatory Biomarkers (08/08/18)   Severe menopausal symptoms double odds of poor ART adherence in UK women - Mark Mascolini (08/08/18)   CD4 count and viral load tied to atherogenic cholesterol in people with HIV - Mark Mascolini (08/07/18)   Vitamin D does not modulate immune-mediated bone loss during ART initiation: A5280 (08/07/18)   Liver enzyme spikes--then normalizes--when elderly start dolutegravir - Mark Mascolini (08/07/18)   Will hepatitis C transmission be eliminated by 2025 among HIV-positive men who have sex with men in Australia? - Mark Mascolini (08/06/18)   Shared HCV transmission networks among HIV-1 positive and HIV-1 negative men having sex with men in Paris (08/06/18)   Statins not linked to lower HIV persistence, inflammation, or immune activation - Mark Mascolini (08/06/18)   Partner Violence: A Significant Part of a Syndemic Among Black Men Who Have Sex With Men (08/06/18)   High uptake of yearly digital rectal exam for anal cancer in Australian MSM with HIV - Mark Mascolini (08/06/18)   COMPLACENCY IS THE NEW PROBLEM: COMPARATIVE ANALYSIS OF RECENT OUTBREAKS OF HIV AMONG PERSONS WHO INJECT DRUGS IN EUROPE AND NORTH AMERICA (08/06/18)   Steep virologic failure drop in Netherlands: initial VL and CD4 strong predictors - Mark Mascolini (08/06/18)   Alcohol screening less likely in blacks, people with AIDS, in big HIV group - Mark Mascolini (08/06/18)   HIV incidence drops in Melbourne MSM, reflecting changing HIV testing and control - Mark Mascolini (08/06/18)   DETERMINANTS OF POST-DISCLOSURE VIOLENCE AGAINST HIV POSITIVE WOMEN IN SERODISCORDANT UNIONS: A CROSSSECTIONAL STUDY IN KUMASI, GHANA (08/06/18)   One third of black MSM in NYC group experience partner violence - Mark Mascolini (08/06/18)   Treatment failure in 20% on ART in Australian group: toxicity main culprit - Mark Mascolini (08/06/18)   A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single-Tablet Regimen in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V and/or M184I (GS-US-292-1824): Week 24 Results (08/06/18)   Eight recent HIV outbreaks in drug injectors point to prevention complacency - Mark Mascolini (08/06/18)   Editorial - Cardiovascular Outcomes in Persons With HIV and Heart Failure Medication Class or Suboptimal Viral Suppression? - Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure (08/03/18)   HIV DNA reservoir size and make-up "remarkably" stable through 20 years of ART - Mark Mascolini (08/03/18)   Possible link between HIV and vestibular impairment in men and women - Mark Mascolini (08/03/18)   Half of adults in HIV group have insomnia--fewer than half of them treated (08/02/18)   Comparison of depression and anxiety between HIV-positive and HIV-negative people.... 3-7 Times Higher Rates for HIV+/Aging Increases Rates (08/02/18)   Population Pharmacokinetics of Cabotegravir in Healthy Adult Subjects and HIV-1 Infected Patients Following Administration of Oral Tablet and Long-Acting Intramuscular Injection (08/02/18)   Half of adults in HIV group have insomnia--fewer than half of them treated - Mark Mascolini (08/02/18)   Quantifying the Relationship Between HIV Patient and Treatment Characteristics, ART Adherence and Viral Suppression Using Contemporary Data (08/02/18)   Kick-and-kill with vaccines plus vorinostat has no impact on CD4 reservoir - Mark Mascolini (08/01/18)   Uptake and Effectiveness of Two-drug Compared to Three-drug Antiretroviral Regimens among HIV-positive Individuals in Europe (08/01/18)   Clinical Effectiveness of Guideline-Recommended Antiretroviral Therapy Core Agents in HIV/HCV Co-infected Patients in the OPERA Observational Database (08/01/18)   Virologic Outcomes Among Treatment Naive HIV+ Patients Initiating Common First Antiretroviral Therapy Core Agents in the OPERA Observational Database (08/01/18)   A Comprehensive Assessment of Hepatobiliary Disorders in HIV-Infected Patients Treated With Dolutegravir, Elvitegravir, Raltegravir or Darunavir in the OPERA Database - Liver Chemistry Elevations/DILI (08/01/18)   Medication errors with Retrovir oral solution in neonates and infants ≤ 23 months (08/01/18)   Comparison of depression and anxiety between HIV-positive and HIV-negative people....3-7 Times Higher Rates for HIV+/Aging Increases Rates (08/01/18)   Healthcare Utilization and STI Incidence in Young Men on Pre-exposure Prophylaxis (PrEP) Compared to Young Men Who Are Not on PrEP: The PrEPARE Study (08/01/18)   Changes, Patterns and Predictors of Sexually Transmitted Infections in Gay and Bisexual Men Using PrEP - Interim Analysis from the PrEPX Study (08/01/18)   PrEP use rising in US MSM, but rectal STI rate remains stable - Mark Mascolini (08/01/18)   Cardiovascular Disease Risk Assessments and Fasting Lipid Changes in Virologically Suppressed Patients Randomized to Switch to Tenofovir Alafenamide versus Continuing Tenofovir Disoproxil Fumarate (08/01/18)   Changes in Cardiovascular Risk Estimation and Fasting Lipids in Virologically Suppressed Patients Randomized to Switch to Tenofovir Alafenamide versus Continuing Abacavir (07/31/18)   Switching from an Abacavir (ABC)/Lamivudine (3TC)-Based Regimen to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF): Cardiovascular Disease Risk Profile Analysis from a Randomized Controlled Study in Virologically-Suppressed Adults (07/31/18)   Noncommunicable disease rates with HIV lower in England than in 4 other countries - Mark Mascolini (07/31/18)   Adherence to Long-Acting CAB and RPV Injections Through 96 Weeks of Maintenance Therapy in LATTE-2 / Good adherence to injected cabotegravir and rilpivirine in 230 LATTE-2 participants - Mark Mascolini (07/31/18)   Virologic Outcomes Among Treatment Naive HIV+ Patients Initiating Common First Antiretroviral Therapy Core Agents in the OPERA Observational Database (07/31/18)   Resistance Through Week 48 in the DAWNING Study Comparing Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/r) Plus 2 NRTIs in Second-line Treatment (07/31/18)   ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018 (07/31/18)   Two-fold higher chance of liver steatosis with HIV in big Brazilian study - Mark Mascolini (07/31/18)   Two-fold higher chance of liver steatosis with HIV in big Brazilian study - Mark Mascolini (07/31/18)   Trends in mortality among HIV-infected subjects; differences by HCV coinfection - 70% of Deaths Non-AIDS: liver-HCV, psychiatric, malignancies, cardiovascular & pulmonary diseases common causes of death (07/31/18)   "Increased risk of both mortality and incident comorbidity among frail HIV-positive and HIV-negative participants and increased risk of frailty progression in those with HIV." (07/31/18)   HIV infection independently increases the risk of developing heart failure: The HIV HEART study - Mark Mascolini (07/30/18)   Very high levels of inflammation marker CRP in young MSM with or without HIV - Mark Mascolini (07/30/18)   Higher depression and anxiety rates with HIV across ART and viral load categories - Mark Mascolini (07/30/18)   Janssen Presents Switch Data for New HIV-1 Treatment SYMTUZA™ (D/C/F/TAF) and Second Study Supporting its Use in a Rapid Initiation Scenario (07/30/18)   Characterization of Doravirine-Selected Resistance Patterns From Participants in Treatment-Naïve Phase 3 Clinical Trials (07/30/18)   Surveillance for Neural Tube Defects following Antiretroviral Exposure from Conception (07/30/18)   Surveillance for Neural Tube Defects following Antiretroviral Exposure from Conception (07/30/18)   HIV-1 subtype (B or non-B) had no impact on the efficacy of B/F/TAF or resistance development in five phase 3 treatment-naïve or switch studies (07/30/18)   IL-10 contributes to and predicts viral persistence in ART-treated, SIV-infected rhesus macaques (07/30/18)   FDA-Approved Chemotherapeutic Drugs that Inhibit VEGF, RAF-1, B-RAF and the Proteosome Reverse HIV-1 Latency Without Global T cell Activation (07/30/18)   Understanding the Resistance Profile of the HIV-1 NNRTI Doravirine in Combination With the Novel NRTTI MK-8591 (07/30/18)   Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: BRIGHTE Week 24 Subgroup Analysis in Randomized Cohort Participants (07/27/18)   Durable Suppression 2 Years After Switch to DTG + RPV 2-Drug Regimen: SWORD-1 and SWORD-2 Studies (07/27/18)   Mortality and cause of death among HIV patients in London in 2016: 77% Die of Non-AIDS Conditions/Comorbidities/majority virally suppressed - Ending AIDS? Only applies to stopping new transmissions? (07/27/18)   Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to <6 years: results from IMPAACT P1093 (07/27/18)   Mortality 4.5 times higher in Canadian women with HIV than in general population - Mark Mascolini (07/27/18)   Patient Satisfaction, Tolerability and Acceptability of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting Therapy in HIV-1-Infected Adults: LATTE-2 Week 96 Results (07/27/18)   Emergence of resistance in HIV-1 Integrase following dolutegravir (DTG) treatment in 6 to <18 year old participants enrolled in the P1093 study (07/27/18)   Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/r) plus 2 NRTIs in second-line treatment - 48-week data from the DAWNING Study (07/27/18)   Pharmacokinetics, Safety, And Efficacy Of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Single-tablet Regimen In Children (6 To <12 Years) Living With HIV-1 (07/27/18)   B/F/TAF vs DTG/ABC/3TC or DTG + F/TAF in Treatment-Naïve Adults With High Baseline Viral Load or Low Baseline CD4 Count in 2 Phase 3 Randomized, Controlled Clinical Trials (07/27/18)   Efficacy and Safety of Switching From Boosted Protease Inhibitor-based Regimens to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide for Treatment of HIV-1 Infection: Subgroups Analysis by Baseline Regimen (07/27/18)   The Impact of Pre-exposure Prophylaxis with FTC/TDF on HIV Diagnoses, 2012-2016, United States (07/27/18)   Among 2590 US adolescents using PrEP, 83.5% are girls, 59% on Medicaid - Mark Mascolini (07/27/18)   Kaposi sarcoma incidence flat among black men in southern US (07/27/18)   Kaposi sarcoma incidence flat among black men in southern US - Mark Mascolini (07/27/18)   Incidence of HIV-infection in the ANRS Prevenir Study in the Paris Region with Daily or On Demand PrEP with TDF/FTC (07/26/18)   Kaposi disease in HIV-infected patients with suppressed HIV viremia: the experience of the French national multidisciplinary committee ONCOVIH - New Kaposi disease in 21 people with 3 years of HIV control in France - Mark Mascolini (07/26/18)   DolPHIN-1: Randomised controlled trial of dolutegravir(DTG)-versus efavirenz(EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy (07/26/18)   INSPIRING: SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV CO-INFECTED ADULTS AT WEEK 48 (07/26/18)   Universal test-and-treat improves population viral suppression in rural South Africa - Mark Mascolini (07/26/18)   Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in a Test-and-Treat Model of Care for HIV-1 Infection: Interim Analysis of the DIAMOND Study (07/26/18)   Adolescent Use of Truvada (FTC/TDF) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States: (2012-2017) (07/26/18)   Adolescent Use of Truvada (FTC/TDF) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States: (2012-2017) (07/26/18)   Global Partners Pledge over $1.2 billion to Launch the MenStar Coalition (HIV in men) (07/26/18)   ViiV Healthcare's commitments to accelerate the availability of dolutegravir for the treatment of HIV in children (07/26/18)   Mortality after ART starts remains higher in women in Americas and Africa than in Europe - Mark Mascolini (07/25/18)   Global Partners Pledge over $1.2 billion to & Launch the MenStar Coalition (HIV in men) - (07/25/18)   Beyond the 60s: Changing co-morbidities in people living with HIV aged over 60 attending clinic in 2010 and 2017 - (07/25/18)   HIV transmission risk through condomless sex in gay couples with suppressive ART: The PARTNER2 Study extended results in gay men - (07/25/18)   The Impact of Pre-exposure Prophylaxis With FTC/TDF on HIV Diagnoses, 2012-2016, United States - (07/25/18)   Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine - (07/25/18)   ViiV Healthcare presents phase III data showing two drug regimen has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no resistance - (07/25/18)   GILEAD SCIENCES PROVIDES GRANT TO AID FOR AIDS INTERNATIONAL TO EXPAND ACCESS TO HIV TREATMENT IN VENEZUELA - (07/25/18)   Gilead Announces New Data on the Impact of Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States - (07/25/18)   Dolutegravir/3TC noninferior to DTG/TDF/FTC at 48 weeks in big ART-naive group - Mark Mascolini (07/25/18)   Antiretroviral therapy (ART) interruption is associated with reduced cortical structures at age 5 years compared to uninterrupted. - (07/25/18)   Doravirine (DOR) Versus Ritonavir-Boosted Darunavir (DRV+r): 96-Week Results of the Randomized, Double-Blind, Phase 3 DRIVE-FORWARD Noninferiority Trial - (07/25/18)   the PARTNER Study: new results from PARTNER 2 - PDF - Q and A - (07/25/18)   Long-term data from APPROACH study - (07/25/18)   Variables Associated With Neuropsychiatric Symptoms in PLWH Receiving Dolutegravir-Based Therapy in Phase III Clinical Trials - (07/25/18)   PARTNER-2 Study No HIV transmissions in 8 years when gay HIV+ partner has undetectable load - Mark Mascolini (07/25/18)   Non-Inferior Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) vs DTG Plus Tenofovir/Emtricitabine (TDF/FTC) Fixed-Dose Combination in Antiretroviral Treatment-Naive Adults With HIV-1 Infection-Week 48 Results From the GEMINI Studies - (07/25/18)   Kick-and-kill with vaccines plus vorinostat has no impact on CD4 reservoir - Written by Mark Mascolini (07/24/18)   ViiV Healthcare presents phase III data showing two drug regimen has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no resistance - (07/24/18)   Rates of kidney and bone disease--and multiple comorbidities--rising in elderly HIV group - Written by Mark Mascolini (07/24/18)   Viral suppression for HIV treatment success and prevention of sexual transmission of HIV - (07/23/18)